Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421442 · ClinicalTrials.gov registry record
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 38,396
- Enrollment target
NCT05421442 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 38,396 participants.
The verdict
NCT05421442 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 38,396 participants
- Enrollment target
Study Summary
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38,396 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2025-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05421442
The ClinicalTrials.gov registry entry for NCT05421442 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38,396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05421442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05421442 about?
NCT05421442 is a clinical study titled "A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database". The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
What is the current status of trial NCT05421442?
This trial is currently completed. The enrollment target is 38,396 participants. The study started on 2019-06-13. Estimated completion is 2025-10-31.
Who is sponsoring clinical trial NCT05421442?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.